

Adlai Nortye opens Boston Innovation Centre

20 August 2018 | News

The Boston site will form the target validation and translational medicine centre of the company.



Adlai Nortye, a Hangzhou biopharma, has announced the opening of its first US site in Boston, Massachusetts. The Boston site was opened by CEO Carsten Lu, CDO Dr. Lars E. Bigerson, M.D., Ph.D. who is also President & CEO of Adlai Nortye USA Inc, and other core management team members.

The Boston site, which will form the target validation and translational medicine centre of the company, is an innovation centre dedicated to the development of important new treatments for cancer, especially immuno-oncology drugs based in the US. The centre will support clinical stage programs of the company and serve as a platform to better integrate Adlai Nortye into the global biopharmaceutical research and development industry.

"Adlai Nortye, unlike other domestic pharmaceutical manufacturers in China used to being associated with the production of "me-too" drugs or "me-better" drugs, aims to innovate through target validation to discover new translational medicines," said CDO and President & CEO of Adlai Nortye USA Inc, Dr. Lars E. Bigerson, M.D., Ph.D. "The establishment of our first overseas site in Boston, will further help us to better integrate into the international biopharmaceutical market as we push forward the development of our treatments."